Huntington National Bank decreased its position in Zimmer Biomet Holdings Inc. (NYSE:ZBH) by 8.4% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 8,128 shares of the company’s stock after selling 748 shares during the period. Huntington National Bank’s holdings in Zimmer Biomet Holdings were worth $978,000 at the end of the most recent quarter.
Other large investors also recently made changes to their positions in the company. Park Avenue Institutional Advisers LLC boosted its stake in Zimmer Biomet Holdings by 1.2% in the first quarter. Park Avenue Institutional Advisers LLC now owns 1,128 shares of the company’s stock worth $120,000 after buying an additional 13 shares during the period. Regent Investment Management LLC acquired a new stake in Zimmer Biomet Holdings during the second quarter worth $217,000. Checchi Capital Advisers LLC boosted its stake in Zimmer Biomet Holdings by 3.7% in the second quarter. Checchi Capital Advisers LLC now owns 1,832 shares of the company’s stock worth $221,000 after buying an additional 66 shares during the period. Atria Investments LLC acquired a new stake in Zimmer Biomet Holdings during the second quarter worth $238,000. Finally, FirstMerit Bank N A Trustee acquired a new stake in Zimmer Biomet Holdings during the second quarter worth $247,000. Institutional investors own 88.32% of the company’s stock.
Shares of Zimmer Biomet Holdings Inc. (NYSE:ZBH) traded down 0.42% during trading on Monday, hitting $126.62. The stock had a trading volume of 741,378 shares. The firm has a 50-day moving average price of $127.99 and a 200 day moving average price of $122.47. The company has a market capitalization of $25.33 billion, a PE ratio of 115.63 and a beta of 0.95. Zimmer Biomet Holdings Inc. has a 52 week low of $88.27 and a 52 week high of $133.21.
Zimmer Biomet Holdings (NYSE:ZBH) last posted its earnings results on Thursday, July 28th. The company reported $2.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.97 by $0.05. Zimmer Biomet Holdings had a return on equity of 16.12% and a net margin of 1.68%. The business earned $1.93 billion during the quarter, compared to analysts’ expectations of $1.90 billion. During the same period in the previous year, the business earned $1.58 earnings per share. The firm’s revenue was up 65.6% on a year-over-year basis. Equities analysts anticipate that Zimmer Biomet Holdings Inc. will post $7.97 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 28th. Investors of record on Friday, September 23rd will be given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a yield of 0.76%. The ex-dividend date is Wednesday, September 21st. Zimmer Biomet Holdings’s payout ratio is 157.38%.
A number of equities research analysts recently weighed in on ZBH shares. Piper Jaffray Cos. restated an “overweight” rating and issued a $125.00 price target on shares of Zimmer Biomet Holdings in a research note on Tuesday, June 21st. Jefferies Group reiterated a “buy” rating and set a $150.00 price objective on shares of Zimmer Biomet Holdings in a research report on Monday, August 8th. Argus reiterated a “buy” rating and set a $140.00 price objective on shares of Zimmer Biomet Holdings in a research report on Thursday, September 22nd. Barclays PLC increased their price objective on Zimmer Biomet Holdings from $140.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 23rd. Finally, RBC Capital Markets set a $143.00 price objective on Zimmer Biomet Holdings and gave the stock a “buy” rating in a research report on Wednesday, September 14th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and twenty-one have given a buy rating to the stock. Zimmer Biomet Holdings has an average rating of “Buy” and an average target price of $133.57.
In related news, insider Stuart G. Kleopfer sold 533 shares of the business’s stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $132.71, for a total transaction of $70,734.43. Following the completion of the transaction, the insider now directly owns 6,397 shares in the company, valued at $848,945.87. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, VP Tony W. Collins sold 1,287 shares of the business’s stock in a transaction dated Friday, August 12th. The stock was sold at an average price of $129.16, for a total value of $166,228.92. The disclosure for this sale can be found here. Corporate insiders own 1.22% of the company’s stock.
About Zimmer Biomet Holdings
Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings Inc. (NYSE:ZBH).
Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.